



8-23-04

JRW

Express Mail No. EV 462 737 763 US

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(e)		
Address to:	Attorney Docket	UCAL-131CON4
Mail Stop	First Named Inventor	PRUSINER, STANLEY B.
Commissioner for Patents	Application Number	10/735,454
P.O. Box 1450	Confirmation No.	2015
Alexandria, VA 22313-1450	Filing Date	December 12, 2003
	Group Art Unit	1616
	Examiner Name	
	Title:	"SODIUM DODECYL SULFATE COMPOSITIONS FOR INACTIVATING PRIONS"

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.


No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. UCAL-131CON4.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: 20/August/04

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231

By:

  
Karl Bozicevic, Reg. No. 28,807

Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/1735,454
				Filing Date	December 12, 2003
				First Named Inventor	PRUSINER, STANLEY B.
				Group Art Unit	1616
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	UCAL-131CON4

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials'	Cite No. <sup>1</sup>	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY
		Office <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)		
		WO 01/54736 A2		The Regents of the University of California	08-02-2001

<b>OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		SUPATTAPONE et al., "Elimination of prions by branched polyamines and implications for therapeutics" PNAS 96(25):14529-14534 (December 7, 1999)			

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.